Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2017
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2017
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Tumor necrosis factor receptor superfamily member 16 plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulin-dependent glucose uptake. Low affinity receptor which can bind to NGF, BDNF, NT-3, and NT-4.
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Report covers products from therapy areas Central Nervous System, Dermatology, Infectious Disease, Ophthalmology and Toxicology which include indications Alzheimer's Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Pain, HIV Related Neurological Diseases, Huntington Disease, Keratoconjunctivitis sicca (Dry Eye), Open-Angle Glaucoma, Osteoarthritis Pain, Retinitis Pigmentosa (Retinitis), Spinal Cord Injury, Traumatic Brain Injury and Wounds.
The latest report Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Tumor necrosis factor receptor superfamily member 16 plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulin-dependent glucose uptake. Low affinity receptor which can bind to NGF, BDNF, NT-3, and NT-4.
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Report covers products from therapy areas Central Nervous System, Dermatology, Infectious Disease, Ophthalmology and Toxicology which include indications Alzheimer's Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Pain, HIV Related Neurological Diseases, Huntington Disease, Keratoconjunctivitis sicca (Dry Eye), Open-Angle Glaucoma, Osteoarthritis Pain, Retinitis Pigmentosa (Retinitis), Spinal Cord Injury, Traumatic Brain Injury and Wounds.
The latest report Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Companies Involved in Therapeutics Development
Chiesi Farmaceutici SpA
Dompe Farmaceutici SpA
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Drug Profiles
cenegermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize P75 Neurotrophin Receptor for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LEVI-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-11A31BHS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize NGFR for Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Product Development Milestones
Featured News & Press Releases
Sep 14, 2017: Levicept Starts First-in-Human Phase I Trial of LEVI-04, A Novel Fusion Protein Therapy for Chronic Pain
Jul 20, 2017: Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompe Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy
Jul 10, 2017: Dompe Farmaceutici Receives EU marketing authorization For OXERVATE
May 23, 2017: Dompe Receives Positive CHMP Opinion in Europe For Oxervate (Cenegermin Eye Drops) For the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis
May 19, 2017: The European Medicines Agency: New medicine for rare eye disease
Dec 12, 2016: EMA Validates the Marketing Authorisation Application for Cenegermin Eye Drops (Oxervate) Submitted by Domp?
Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
Nov 22, 2014: Italian research at the SOI Congress: focus on therapeutic prospects of NGF, the innovative molecule developed on the basis of the studies by Rita Levi Montalcini in ophthalmology
Sep 25, 2014: EuCornea: Dompe wins the “Best Poster Award” for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis
Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis
Apr 03, 2014: First Patient is Enrolled in Lumos Study. Objective: to Evaluate Safety and Potential Efficacy of rhNGF in the Treatment of Retinitis Pigmentosa
Sep 11, 2013: Domp? Announces the Food and Drugs Administration Has Granted Orphan Drug Designation to its rhNGF-based Treatment for Retinitis Pigmentosa
Jul 01, 2013: Domp? Announces the EMA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa
Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis
Sep 07, 2012: Domp? Initiates Phase I Clinical Trial On Use Of Recombinant Human Nerve Growth Factor For Treating Neurotrophic Keratitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Companies Involved in Therapeutics Development
Chiesi Farmaceutici SpA
Dompe Farmaceutici SpA
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Drug Profiles
cenegermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize P75 Neurotrophin Receptor for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LEVI-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-11A31BHS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize NGFR for Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Product Development Milestones
Featured News & Press Releases
Sep 14, 2017: Levicept Starts First-in-Human Phase I Trial of LEVI-04, A Novel Fusion Protein Therapy for Chronic Pain
Jul 20, 2017: Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompe Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy
Jul 10, 2017: Dompe Farmaceutici Receives EU marketing authorization For OXERVATE
May 23, 2017: Dompe Receives Positive CHMP Opinion in Europe For Oxervate (Cenegermin Eye Drops) For the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis
May 19, 2017: The European Medicines Agency: New medicine for rare eye disease
Dec 12, 2016: EMA Validates the Marketing Authorisation Application for Cenegermin Eye Drops (Oxervate) Submitted by Domp?
Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
Nov 22, 2014: Italian research at the SOI Congress: focus on therapeutic prospects of NGF, the innovative molecule developed on the basis of the studies by Rita Levi Montalcini in ophthalmology
Sep 25, 2014: EuCornea: Dompe wins the “Best Poster Award” for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis
Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis
Apr 03, 2014: First Patient is Enrolled in Lumos Study. Objective: to Evaluate Safety and Potential Efficacy of rhNGF in the Treatment of Retinitis Pigmentosa
Sep 11, 2013: Domp? Announces the Food and Drugs Administration Has Granted Orphan Drug Designation to its rhNGF-based Treatment for Retinitis Pigmentosa
Jul 01, 2013: Domp? Announces the EMA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa
Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis
Sep 07, 2012: Domp? Initiates Phase I Clinical Trial On Use Of Recombinant Human Nerve Growth Factor For Treating Neurotrophic Keratitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Chiesi Farmaceutici SpA, H2 2017
Pipeline by Dompe Farmaceutici SpA, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Chiesi Farmaceutici SpA, H2 2017
Pipeline by Dompe Farmaceutici SpA, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Chiesi Farmaceutici SpA
Dompe Farmaceutici SpA
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
Chiesi Farmaceutici SpA
Dompe Farmaceutici SpA
